REPRIEVE and the ACTG Network will issue a request for proposals (RFP) for data requests. The RFP will be open to investigators at REPRIEVE sites (both ACTG and REPRIEVE protocol-specific sites). At the current time, this request is limited to data, including clinical data and currently available lab and biomarker data. Requests for samples may be considered in a future RFP.
Please review this page in detail for instructions and resources related to this RFP. Available resources include the REPRIEVE protocol (which contains a schedule of evaluations), the REPRIEVE Manual of Procedures (MOPS), the REPRIEVE Publications Standard Operating Procedures (SOP), available labs and biomarkers, baseline characteristics of REPRIEVE participants and available clinical outcomes, and dataset availability. Also below is a list of biomarkers currently undergoing analysis. These biomarker data are not yet available for the purposes of this RFP. When this biomarker data is available, subsequent opportunities to utilize this data will be made available.
This RFP will take place in two stages. First, investigators will submit a Letter of Intent (LOI) via the ACTG website by September 30, 2024. If there are overlapping LOIs submitted, investigators with such LOIs will be contacted by the ACTG to facilitate collaboration. In December 2024, between 15-20 LOIs will be selected to move forward and investigators will receive further instructions to submit a proposal.
Second, investigators will submit a proposal via the ACTG website in January 2025. Between 7-10 meritorious proposals will be selected, based on scientific importance, availability of data, nonoverlap with any past, current or planned proposals, feasibility, and robustness of the statistical plan.
Decisions will be announced in March 2025. Depending on data availability and resources, subsequent RFP’s may be issued for REPRIEVE data. Highly ranked projects not accepted in the first RFP may be resubmitted in a subsequent RFP for REPRIEVE data sharing. The REPRIEVE Publications SOP outlines requirements and next steps for subsequent manuscript development.
Please review the list of current projects approved and under development by the REPRIEVE team, the REPRIEVE Ancillary Studies, and past REPRIEVE manuscripts before beginning a submission for this RFP and to ensure that there is not overlap with a past or ongoing REPRIEVE project. The current projects below largely represent prespecified Aims of the original REPRIEVE grant, supplementally funded Aims, and/or planned investigations of relevant areas of interest. Proposals submitted through this RFP for projects that were completed or are already underway cannot be approved. However, REPRIEVE will continue to solicit interest and create opportunities for site investigators to join the authorship teams of existing projects.
Authorship: The lead author will submit a list of potential co-authors based on contribution and/or planned contribution with the initial proposal to the ACTG. For accepted proposals, at least one REPRIEVE Chair and Vice Chair and additional co-authors (based on contribution to the main trial, expertise, and equitable sharing of opportunities) will be assigned to each proposal and subsequent manuscripts. The final list of authors and author order will be approved by the REPRIEVE Publications and Executive Committees. All authors must meet ICMJE authorship requirements. Further details about authorship can be found in the REPRIEVE Publications SOP.
Budget: Writing teams must pursue their own sources of statistical funding and outline that source in the proposal. If the proposal requests analysis support by the REPRIEVE statistical core, the proposed effort, sources of support and methodologies to be used for this analysis must be outlined. If a proposal is under consideration for approval, proposers will be given an opportunity to estimate statistical effort with the REPRIEVE statistical core. If a statistical analysis is to occur outside the REPRIEVE statistical core, the analysis and proposed statistical team must be approved by the REPRIEVE statistical core, with sources of support outlined.
Click here to submit a proposal to the ACTG CTSG for review
Click here for the REPRIEVE protocol
Click here for the REPRIEVE Manual of Procedures (MOPs)
Click here for the REPRIEVE Publications Standard Operating Procedures (SOP)
Click here for a Testing Completeness Report which includes available labs and biomarkers
Click here for a list of baseline characteristics of REPRIEVE participants and available clinical outcomes
Click here for a list of the REPRIEVE analysis datasets
Click here for a list of future biomarkers undergoing analysis in REPRIEVE (A5332)*
*These biomarkers are not yet available for the purposes of this RFP. When this biomarker data is available, subsequent opportunities to utilize this data will be made available.
Current Projects Approved and Under Development by the REPRIEVE Team*
*Additional projects may be in the planning stage by the REPRIEVE Team.
Click here to learn about the REPRIEVE Ancillary Studies
Click here to review past REPRIEVE publications
REPRIEVE Main Study (A5332)
- Performance of the ACC/AHA Pooled Cohort Equations in REPRIEVE and Recalibration
Lead Author(s): Steve Grinspoon, Markella Zanni, Pamela Douglas - Prognostic Factors of Major Adverse Cardiovascular Events
Lead Author(s): Markella Zanni, Steve Grinspoon - Statin Effects on Non-CVD Endpoints/Non-Adjudicated Events (START Endpoint)
Lead Author(s): Marissa Diggs, Triin Umbleja - Effects of Antiretroviral Therapy Exposure (Never/Former/Current) on Major Adverse Cardiovascular Events
Lead Author(s): Carl Fichtenbaum, Carlos Malvestutto - Effects of NRTI (Abacavir, TDF, TAF) on Major Adverse Cardiovascular Events
Lead Author(s): Carlos Malvestutto, Carl Fichtenbaum, Emma Davies Smith - Predictors of Incident Diabetes and Statin Effects
Lead Author(s): Kathleen Fitch, Steve Grinspoon - Statin Effects on COVID-19 Outcomes
Lead Author(s): Markella Zanni, Triin Umbleja - Statin Effects on Cognitive Function in REPRIEVE and HAILO
Lead Author(s): Kristine Erlandson - Effects of INSTIs on Blood Pressure and the Mediating Effects of Kidney Function and BMI
Lead Author(s): Alana Brennan, Emma Kileel, Jen Manne-Goehler - Cost and Cost-Effectiveness of Pitavastatin to Prevent Cardiovascular Disease in People with HIV
Lead Author(s): Thomas Mayrhofer, Michael Lu - Analysis of a Frailty Index in REPRIEVE
Lead Author(s): Ariela Orkaby, Alan Landay, George Kuchel, Kristine Erlandson - Global Burden of Disease Effects on Major Adverse Cardiovascular Events
Lead Author(s): Gerald Bloomfield, Pamela Douglas - Heart Failure and Heart Failure Risk Factors in REPRIEVE
Lead Author(s): Gerald Bloomfield, Pamela Douglas - Mechanisms of Pitavastatin Effects: LDL vs. inflammation
Lead Author(s): Steve Grinspoon, Pamela Douglas - Statin Effects and Role of Other Lipids in Cardiovascular Disease: TGL, HDL, lp(a)
Lead Author(s): Steve Grinspoon, Pradeep Natarajan - Predictors of Weight Change and INSTI Effects
Lead Author(s): Emma Kileel, Steve Grinspoon - Life's Essential 8 and Major Adverse Cardiovascular Events
Lead Author(s): Pamela Douglas, Steve Grinspoon - Predictors of Myalgia in REPRIEVE
Lead Author(s): Kristine Erlandson - Statin Effects on Cancer
Lead Author(s): Steve Grinspoon - Sex and Reproductive Aging Effects on Major Adverse Cardiovascular Events
Lead Author(s): Markella Zanni - Personalized Prediction Effects of Statins
Lead Author(s): Evelyne Zhang - EKG Predictors of Major Adverse Cardiovascular Events
Lead Author(s): Gerald Bloomfield, Pamela Douglas - ECG Features and Risk of Sudden Cardiac Death in REPRIEVE
Lead Author(s): Christopher deFilippi, Stephen Wiviott, Pamela Douglas, Steve Grinspoon
REPRIEVE Mechanistic Substudy (A5333s)
- Health-Related Quality of Life and Atherosclerotic Cardiovascular Disease
Lead Author(s): Marissa Diggs, Kathleen Fitch - Statin Effects on Transcriptomics and Related Outcomes (Plaque, Diabetes, Liver, and Others)
Lead Author(s): Steve Grinspoon - Statin Effects on Pericoronary Fat Attenuation (PCAT) and Epicardial Fat
Lead Author(s): Borek Foldyna - HIV, Cardiovascular Disease Risk and Coronary Atherosclerosis: A cross-country comparison between the United States and Uganda
Lead Author(s): Mark Siedner, Brian Ghoshhajra - Epigenetic Aging in REPRIEVE
Lead Author(s): Michael Corley, Alan Landay, Kristine Erlandson, Steve Grinspoon - REPRIEVE Mechanistic Substudy Biomarkers Analysis
Lead Author(s): Michael Lu, Steve Grinspoon - Association Between Risk Factors, Inflammatory Markers and Coronary Atherosclerotic Radiomic Phenotypes in People with HIV
Lead Author(s): Marton Kolossvary, Michael Lu - Proteomics Analysis of INSTI Use in REPRIEVE
Lead Author(s): Marton Kolossvary, Emma Kileel - Plaque Presence, Progression, and MACE in the REPRIEVE Mechanistic Substudy
Lead Author(s): Michael Lu, Steve Grinspoon - Individual Plaque Analyses in the REPRIEVE Mechanistic Substudy
Lead Author(s): Michael Lu, Borek Foldyna, Thomas Mayrhofer, Heather Ribaudo - Statin Effects on Coronary Plaque Composition and Calcification
Lead Author(s): Michael Lu, Borek Foldyna - Machine Learning Prediction of Coronary Plaque, Plaque Progression, and Major Adverse Cardiovascular Events
Lead Author(s): Michael Lu - Computational Fluid Dynamics to Predict Coronary Plaque and Plaque Progression
Lead Author(s): Michael Lu - Prognostic Factors of Plaque Progression
Lead Author(s): Michael Lu - Aortic Plaque and Inflammation
Lead Author(s): Michael Lu, TBD - Cardiac Morphology and Changes with Statins
Lead Author(s): Michael Lu, Borek Foldyna - Lung Health and Inflammation with Statin Therapy
Lead Author(s): Michael Lu, TBD - Incidental Findings on Cardiac CT in HIV
Lead Author(s): Nina Meyersohn, Sandeep Hedgire, Michael Lu - Antiretroviral Therapy and Coronary Artery Plaque
Lead Author(s): REPRIEVE Substudy Team - Longitudinal Analysis of Metabolic Dysfunction-Associated Steatotic Liver Disease
Lead Author(s): REPRIEVE Substudy Team - Effects of Sex Hormones on Coronary Artery Plaque
Lead Author(s): Markella Zanni, Sara Looby
REPRIEVE Ancillary Studies
- Proteinuria and Albuminuria in REPRIEVE: Prevalence and Associated Factors
Lead Author(s): E Turner Overton - Statin Effects on Muscle Function and Frailty in PREPARE
Lead Author(s): Kristine Erlandson - Statin Effects on Cardiac Structure and Function
Lead Author(s): Tom Neilan, Markella Zanni - Longitudinal Analysis of Kidney Function in REPRIEVE
Lead Author(s): E Turner Overton - Clonal Hematopoiesis of Indeterminate Potential and Major Adverse Cardiovascular Events
Lead Author(s): Romit Bhattacharya, Aniruddh Patel, Pradeep Natarajan - Polygenic Risk Scores and Major Adverse Cardiovascular Events
Lead Author(s): Aniruddh Patel, Roger Zou, Romit Bhattacharya, Pradeep Natarajan - Sex Differences in Statin-Induced Immunomodulation
Lead Author(s): Markella Zanni, Sara Looby - Effects of Reproductive Aging vs. Chronologic Aging on ASCVD Events in Women
Lead Author(s): Sara Looby, Markella Zanni - Genetics of Diabetes in REPRIEVE
Lead Author(s): Luke Wander, Josep Mercader